[go: up one dir, main page]

ECSP19062769A - Formulación de anticuerpo monoclonal anti-vrs - Google Patents

Formulación de anticuerpo monoclonal anti-vrs

Info

Publication number
ECSP19062769A
ECSP19062769A ECSENADI201962769A ECDI201962769A ECSP19062769A EC SP19062769 A ECSP19062769 A EC SP19062769A EC SENADI201962769 A ECSENADI201962769 A EC SENADI201962769A EC DI201962769 A ECDI201962769 A EC DI201962769A EC SP19062769 A ECSP19062769 A EC SP19062769A
Authority
EC
Ecuador
Prior art keywords
vrs
monoclonal anti
antibody formulation
formulation
present
Prior art date
Application number
ECSENADI201962769A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP19062769A publication Critical patent/ECSP19062769A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/104—
    • C07K16/11—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una formulación que comprende: (i) un anticuerpo monoclonal anti-VRS; y (ii) un excipiente iónico; en donde el anticuerpo monoclonal está presente a una concentración de aproximadamente 50 mg/ml o más y el excipiente iónico está presente a una concentración de entre 50 y 150 mM y la formulación tiene un pH de aproximadamente 5.5 a aproximadamente 7.5.
ECSENADI201962769A 2017-03-01 2019-08-29 Formulación de anticuerpo monoclonal anti-vrs ECSP19062769A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762465379P 2017-03-01 2017-03-01

Publications (1)

Publication Number Publication Date
ECSP19062769A true ECSP19062769A (es) 2019-09-30

Family

ID=61903153

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201962769A ECSP19062769A (es) 2017-03-01 2019-08-29 Formulación de anticuerpo monoclonal anti-vrs

Country Status (24)

Country Link
US (4) US10774133B2 (es)
EP (1) EP3589648A4 (es)
JP (2) JP7046088B2 (es)
KR (2) KR102668158B1 (es)
CN (3) CN110418803B (es)
AR (1) AR111083A1 (es)
AU (2) AU2018227502B2 (es)
BR (1) BR112019017755A2 (es)
CA (1) CA3051864A1 (es)
CL (1) CL2019002478A1 (es)
CO (1) CO2019009034A2 (es)
CR (1) CR20190400A (es)
EA (1) EA201991701A1 (es)
EC (1) ECSP19062769A (es)
GB (1) GB2564175B (es)
IL (2) IL312499A (es)
MX (1) MX2019010408A (es)
MY (1) MY206022A (es)
PH (1) PH12019501979A1 (es)
SG (1) SG11201906853QA (es)
TW (1) TWI761453B (es)
UA (1) UA128450C2 (es)
WO (1) WO2018160722A1 (es)
ZA (1) ZA202006797B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AU2015206570A1 (en) 2014-01-15 2016-07-14 Medimmune, Llc RSV-specific antibodies and functional parts thereof
EP4606820A3 (en) * 2015-11-30 2025-10-29 Medimmune, LLC Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CN110366429B (zh) * 2017-03-01 2024-10-11 免疫医疗有限公司 单克隆抗体的配制品
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
SG11202103907PA (en) * 2018-10-18 2021-05-28 Merck Sharp & Dohme Formulations of anti-rsv antibodies and methods of use thereof
AU2019377456A1 (en) 2018-11-07 2021-05-27 Merck Sharp & Dohme Llc Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
PH12021551916A1 (en) 2019-02-18 2022-05-23 Lilly Co Eli Therapeutic antibody formulation.
EP3956351A1 (en) * 2019-04-18 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biological and synthetic molecules inhibiting respiratory syncytial virus infection
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
CR20220545A (es) 2020-03-26 2023-01-09 Univ Vanderbilt ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
CN116987183B (zh) * 2022-07-22 2024-10-15 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
WO2024120517A1 (zh) * 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2230116A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CN1292655C (zh) * 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
AU2013201261B2 (en) 2002-06-14 2016-06-23 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2519408C (en) * 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
AU2007223903B2 (en) * 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2346990B1 (en) 2008-11-05 2016-01-06 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
NZ599148A (en) 2009-10-06 2014-08-29 Medimmune Ltd Rsv-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CL2011003002A1 (es) 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
SI2950886T1 (sl) 2013-02-01 2020-06-30 Medimmune, Llc Epitopi proteina F respiratornega sincicijskega virusa
AU2015206570A1 (en) 2014-01-15 2016-07-14 Medimmune, Llc RSV-specific antibodies and functional parts thereof
MX2017004975A (es) * 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
EP3821906A1 (en) 2015-07-07 2021-05-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv comprising modified f polypeptide
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
CN110366429B (zh) * 2017-03-01 2024-10-11 免疫医疗有限公司 单克隆抗体的配制品
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies

Also Published As

Publication number Publication date
UA128450C2 (uk) 2024-07-17
AR111083A1 (es) 2019-05-29
NZ755790A (en) 2024-04-26
WO2018160722A1 (en) 2018-09-07
EP3589648A4 (en) 2020-12-23
TW201840334A (zh) 2018-11-16
US20210317191A1 (en) 2021-10-14
CN110418803B (zh) 2024-01-19
CR20190400A (es) 2019-12-03
IL268202B1 (en) 2024-06-01
US20200339667A1 (en) 2020-10-29
JP7446356B2 (ja) 2024-03-08
CO2019009034A2 (es) 2019-08-30
EA201991701A1 (ru) 2020-03-04
US11667698B2 (en) 2023-06-06
AU2022263564A1 (en) 2022-12-15
KR102359181B1 (ko) 2022-02-08
SG11201906853QA (en) 2019-09-27
IL268202B2 (en) 2024-10-01
AU2018227502B2 (en) 2022-08-11
KR102668158B1 (ko) 2024-05-23
GB201802974D0 (en) 2018-04-11
EP3589648A1 (en) 2020-01-08
GB2564175A (en) 2019-01-09
MY206022A (en) 2024-11-25
CL2019002478A1 (es) 2020-01-24
IL268202A (en) 2019-09-26
JP2022095697A (ja) 2022-06-28
AU2022263564B2 (en) 2025-05-22
CN116059343A (zh) 2023-05-05
US20230399383A1 (en) 2023-12-14
IL312499A (en) 2024-07-01
BR112019017755A2 (pt) 2020-04-07
US11286294B2 (en) 2022-03-29
TW202228779A (zh) 2022-08-01
JP2020509031A (ja) 2020-03-26
US10774133B2 (en) 2020-09-15
ZA202006797B (en) 2023-03-29
KR20220020420A (ko) 2022-02-18
JP7046088B2 (ja) 2022-04-01
CA3051864A1 (en) 2018-09-07
US20180251526A1 (en) 2018-09-06
KR20190125318A (ko) 2019-11-06
CN117982637A (zh) 2024-05-07
TWI761453B (zh) 2022-04-21
MX2019010408A (es) 2019-12-19
CN110418803A (zh) 2019-11-05
PH12019501979A1 (en) 2020-06-29
GB2564175B (en) 2021-12-08
AU2018227502A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
ECSP19062769A (es) Formulación de anticuerpo monoclonal anti-vrs
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
AR108240A1 (es) Formulaciones que contienen anticuerpos
MX387451B (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
UA122478C2 (uk) Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
PE20191796A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
CR20220545A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
PE20191242A1 (es) Formulaciones de anticuerpo y metodos
GT201100181A (es) "inhibidores de proteina cinasa"
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
MX385109B (es) Formulaciones de anticuerpos.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
PE20191476A1 (es) Nueva formulacion estable de anticuerpos anti-fxia
PE20150190A1 (es) Formulacion farmaceutica
BR112019023981A2 (pt) injeção de octreotida
AR132013A2 (es) Composición de propionato de calcio y agua
MX2021012848A (es) Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.